Home / "Maneesh" Pharmaceuticals / Corporate Profile / History
 

History

Maneesh Pharmaceuticals incepted in 1975 with a small trading facility of providing biological raw materials, with a gradual expansion in Manufacturing of Generics followed by formulations and marketing of breakthrough brands.
Today, we have got good reach in International markets and we aim for further expansion.
Our achievements in the past two decades are not just milestones but are pillars of our success.

   
  • An integrated pharma player with a strong and well- balanced portfolio of:
  • Product offerings - Branded formulations, OTC, generic for global markets
  • Geographical market served - two of the fastest growing economies in the world (India, Brazil) & one of the largest market for pharma product (Europe).
  • Competencies in-house – R&D, CRO, Regulatory, Global Manufacturing & Distribution
  • Manufacturing Assets – in India, US, and Brazil, accredited by global agencies like FDA and UK MHRA
  • Proven management track record of strategic foresight and smart execution
  • From contract manufacturing to straddling the entire value chain, via organic and inorganic routes in < 10 years
  • Poised for substantial growth, with key drivers being:
  • Domestic Branded formulation and FMCG offerings
  • Improving fundamentals of overseas assets
  • Group synergies
   
  • International Patents for Anti-TB formulations in a single dose sachet
  • Built USFDA compliant manufacturing facility at Himachal Pradesh
  • R & D Centre
   
  • Acquisition of ‘Phaarmasia' Hyderabad , a recognized manufacturing facility for Oral - Contraceptives
  • Clinical Research Organization commenced
  • Tie up with ‘Se-Cure' Pharmaceuticals Israel, for the sole marketing  & distribution rights in India for unique product ‘Femarelle'
  • Acquired marketing & distribution countrywide from Pune based Pure Health Products Pvt. Ltd. & merged with Maneesh Healthcare
   
  • Acquired domestic marketing & distribution countrywide from Sigma labs.
  • Independent Antibiotic Facility Commenced
  • Svizera-Europe Tie Up
  • Proud recipient of the 3G- 2004 award for Introduction of rationalized Fixed Dose Combination of 2, 3 and 4 Anti TB drugs in Sachet.

   
  • Launch Of 4 Fixed Dose Combination In Sachet, First Time In The World
  • Amoxicillin Clavulanate With Lactic Acid Bacillus For The First Time In The World
  • WHO-Geneva Approval
   
  • Supply Of Anti-TB Drugs in 77 Countries Trough WHO-Global Drug Facility
  • Acquired Glaxo Facility Dedicated To Hormones Approved By Glaxo SmithKline Plc UK
   
  • First Time 4 FDC tablet Approved By WHO-Global Drug Facility For Worldwide Program
  • Installed Imported, hi tech Sophisticated Machinery
   
  • First 3 FDC In Single Dose Formulations For TB
   
  • First 4 Fixed Dose Combination As Per WHO Recommendations
  • Dedicated Anti-TB Manufacturing Facility
   
  • Tie Up With Medical Export Group (Netherlands)
   
  • Exports Commenced
   
  • WHO-GMP For The First Plant In Mumbai

 

Corporate Profile  |  HR Initiatives  |  Research  |  Quality Care  |  News Room |  For the Society
"Maneesh" Pharmaceuticals |  Manufacturing Excellence  |  International Presence  |  Products  
"Maneesh" for Doctors  |  Our Team  |  For the Patients  
Contact Us  |  Feedback  |  Site Map  | Search Maneesh